ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
24.76
+0.55 (2.29%)
At close: Sep 18, 2025, 4:00 PM EDT
24.30
-0.45 (-1.84%)
After-hours: Sep 18, 2025, 7:45 PM EDT
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $264.57M in the quarter ending June 30, 2025, with 9.34% growth. This brings the company's revenue in the last twelve months to $1.02B, up 14.41% year-over-year. In the year 2024, ACADIA Pharmaceuticals had annual revenue of $957.80M with 31.85% growth.
Revenue (ttm)
$1.02B
Revenue Growth
+14.41%
P/S Ratio
4.05
Revenue / Employee
$1,557,928
Employees
654
Market Cap
4.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ACAD News
- 6 days ago - Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology - Business Wire
- 10 days ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 23 days ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
- 24 days ago - Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer - Business Wire
- 6 weeks ago - ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - Business Wire
- 6 weeks ago - Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference - Business Wire